BrightSpring Health Services, Inc. 6.75% Preferred Stock due 2027

Company Overview

Business Model: BrightSpring Health Services, Inc. is a leading home and community-based healthcare services platform, focused on delivering complementary pharmacy and provider services to complex patients. The Company operates an integrated and scaled model addressing critical services for high-need and high-cost Senior and Specialty patients, including Behavioral populations. Its platform provides clinical and supportive care services in lower-cost home and community settings, primarily to Medicare, Medicaid, and commercially-insured populations. This includes daily medication therapy management through a national pharmacy infrastructure and clinical services such as home health, hospice, rehab therapy, and home-based primary care.

Market Position: BrightSpring Health Services, Inc. is one of the largest independent providers of home and community-based health services in the United States, serving a market of over $2.0 trillion for high-need and high-cost Senior and Specialty patients. The Company serves over 465,000 patients daily through approximately 10,500 clinical providers and pharmacists across all 50 states, with co-location of pharmacy and provider services in 40 states. Key quality metrics include 99.99% pharmacy order accuracy, 99.34% order completeness, 100% patient satisfaction in outpatient rehab services, an 87% overall rating of care in hospice, and a 35% lower hospitalization rate than the national average in its home-based primary care.

Recent Strategic Developments:

• Divestiture: On January 17, 2025, BrightSpring Health Services, Inc. entered into a definitive agreement to divest its Community Living business for $835 million, subject to customary adjustments. The transaction is expected to close in the first fiscal quarter of 2026, aiming to streamline service offerings and increase focus on Senior and Specialty populations.
• Acquisitions: In 2025, the Company completed three acquisitions within its Provider Services segment for an aggregate consideration of $247.0 million. This included the Amedisys and LHC Branches Acquisition, comprising 110 home health and hospice care centers, with 107 branches closed in 2025 for $238.5 million.
• Initial Public Offering (IPO): In January 2024, BrightSpring Health Services, Inc. completed its IPO, issuing 53,333,334 shares of common stock at $13.00 per share and 8,000,000 6.75% Tangible Equity Units.
• Debt Refinancing: A portion of the IPO proceeds was used to repay $343.3 million of the First Lien Term Loan Facility and all borrowings under the Second Lien Facility in 2024. The remaining First Lien debt was refinanced into a new Tranche B-4 Term Loan, and subsequently into a Tranche B-5 Term Loan in December 2024.
• Share Repurchases: In October 2025, the Company repurchased 1,500,000 shares of common stock for $43.2 million in connection with a secondary offering, fully utilizing the authorized repurchase capacity.
• Operational Initiatives: BrightSpring Health Services, Inc. continues to build out its Home-Based Primary Care model, launched the CCRx medication therapy and risk management program, and established a Clinical (Nursing) Hub for care coordination. The Company opened 7 de novo offices in 2025, contributing to a total of 150 de novo offices since January 1, 2018.

Geographic Footprint: BrightSpring Health Services, Inc. operates across all 50 states in the United States and has a minor presence in Canada. Approximately 53% of the Company's total revenue for the year ended December 31, 2025, was generated from its top 10 states of operation. The Company serves approximately 330,000 patients in their homes daily, operating from approximately 7,700 offices, customer locations, and group homes.

Financial Performance

Revenue Analysis

Profitability Metrics (2025):

• Gross Margin: 11.8%
• Operating Margin: 2.3%
• Net Margin: 0.8%

Investment in Growth:

• R&D Expenditure: Not explicitly disclosed as a separate line item.
• Capital Expenditures: $95.5 million
• Strategic Investments: $247.0 million (aggregate consideration for acquisitions in 2025)

Business Segment Analysis

Pharmacy Solutions

Financial Performance:

• Revenue: $11,445.8 million (+30.7% YoY)
• Operating Income: $436.3 million
• Operating Margin: 3.8%
• Key Growth Drivers: Increase in revenue per prescription dispensed and volume growth, particularly in specialty branded drugs. Infusion and Specialty Pharmacy prescriptions grew over 27%, and Home and Community Pharmacy prescriptions grew over 3% from December 2024 to December 2025.

Product Portfolio:

• Daily medication therapy management, home and in-clinic infusion services, oncology and other specialty patient services, medication services for residents of independent and senior living communities, hospice care, neuro clients' and patients' homes, skilled nursing and rehabilitation facilities, hospital patients, and Seniors with polypharmacy needs.
• Key programs include CCRx for longitudinal medication therapy and risk management.

Market Dynamics:

• BrightSpring Health Services, Inc. is a leading independent pharmacy provider in its markets, leveraging its national scale for purchasing, operations, and payor contracting. The Company has exclusive or preferred relationships for 149 limited distribution oncology drugs, with an additional 18 in the pipeline.

Provider Services

Financial Performance:

• Revenue: $1,464.8 million (+11.1% YoY)
• Operating Income: $205.2 million
• Operating Margin: 14.0%
• Key Growth Drivers: Volume growth and rate increases. Home Health Care services census grew approximately 9%, and rehab hours served grew approximately 12% from December 2024 to December 2025.

Product Portfolio:

• Clinical and supportive care services for approximately 16,000 Senior and Specialty populations. Includes home health, hospice, rehab therapy (physical, speech, occupational, and ABA), supportive care for activities of daily living, and home-based primary care.

Market Dynamics:

• The segment benefits from the aging baby boomer population, with Seniors comprising a significant majority of patients. Home-based health services are increasingly preferred and supported by payors due to their lower cost and ability to reduce hospitalizations.

Sub-segment Breakdown:

• Home Health Care: $767.9 million revenue (+17.2% YoY), 31,135 average daily census (+9.1% YoY).
• Rehab Care: $294.7 million revenue (+6.5% YoY), 7,127 persons served (+8.0% YoY).
• Personal Care: $402.2 million revenue (+4.2% YoY), 16,079 persons served (+1.3% YoY).

Capital Allocation Strategy

Shareholder Returns:

• Share Repurchases: $43.2 million (1,500,000 shares) in October 2025.
• Dividend Payments: BrightSpring Health Services, Inc. has no current plans to pay cash dividends on its common stock.
• Future Capital Return Commitments: The authorized share repurchase program was fully utilized as of December 31, 2025.

Balance Sheet Position:

• Cash and Equivalents: $88.4 million
• Total Debt: $2,569.7 million
• Net Cash Position: $(2,481.3) million (Net Debt)
• Debt Maturity Profile:
  • 2026: $52.3 million
  • 2027: $32.1 million
  • 2028: $40.5 million
  • 2029: $25.5 million
  • 2030: $25.5 million
  • Thereafter: $2,393.6 million The First Lien Term Loan Facility matures on February 21, 2031, the Revolving Credit Facility matures on June 30, 2028, and the Amortizing Notes mature on February 1, 2027.

Cash Flow Generation:

• Operating Cash Flow: $490.2 million
• Free Cash Flow: $394.7 million

Operational Excellence

Production & Service Model: BrightSpring Health Services, Inc. employs a differentiated, integrated, and scaled care delivery model focused on high-touch, coordinated services for medically complex patients. Its pharmacy segment operates a local model with over 175 pharmacies, infusion centers, and specialty oncology locations across all 50 states, fulfilling over 43 million prescriptions in 2025 with 99.99% order accuracy. The Provider Services segment delivered approximately 21 million hours of care in 2025. The Company leverages centralized intake, order entry, and a dedicated Project Management Office (PMO) for continuous improvement, which generated approximately $84.7 million in annual savings in 2025.

Supply Chain Architecture: Key Suppliers & Partners:

• Pharmaceutical Wholesalers & GPOs: Purchases generic and brand pharmaceuticals through agreements.
• Drug Manufacturers: Direct purchases of branded and generic pharmaceuticals, with exclusive or preferred relationships for specialty oncology drugs.

Facility Network:

• Manufacturing: Not applicable.
• Research & Development: Focuses on investments in technology and information systems, including EMR/ERP systems, cloud-based data lakes, business intelligence, and robotic process automation.
• Distribution: Operates from approximately 7,700 office, clinic, and customer locations, including over 175 pharmacies, infusion centers, and specialty oncology locations.

Operational Metrics:

• Pharmacy Order Accuracy: 99.99%
• Pharmacy Order Completeness: 99.34%
• Infusion & Specialty Pharmacy Time-to-First-Fill: 4.1 days (vs. industry average of 8.5 days)
• Medication Possession Ratio (MPR): 92.4% (vs. 80% compliance threshold)
• Generic Efficiency Rate: 99.95%
• Average Savings per Therapeutic Interchange: $88
• Outpatient Rehab Patient Satisfaction: 100%
• Hospice Overall Rating of Care: 87% (vs. national average of 81%)
• Home-Based Primary Care Hospital Readmission Rate: 35% lower than national average
• Home Health Branches with STAR rating of 4 or higher: 91%
• Annual Savings from Continuous Improvement Program: $84.7 million (2025)
• Quality and Compliance Team: 208 enterprise oversight members conducting approximately 350 deep audits annually.
• Accredited Locations: Over 550 pharmacies, branches/agencies, and service locations accredited by leading national and third-party bodies.

Market Access & Customer Relationships

Go-to-Market Strategy: Distribution Channels:

• Direct Sales: Utilizes a team of clinical/account liaisons, patient care coordinators, clinicians, and operators to build and maintain professional relationships with referral sources.
• Channel Partners: Engages with physicians, specialists, hospitals, senior living providers, behavioral providers, hospice providers, skilled nursing and rehabilitation providers, pharmaceutical manufacturers, and other health providers. Also works with Accountable Care Organizations (ACOs) and Managed Care Organizations (MCOs).
• Digital Platforms: Employs traditional and digital marketing initiatives.

Customer Portfolio: Enterprise Customers:

• Tier 1 Clients: Serves major enterprise relationships including senior living communities, behavioral providers, skilled nursing and rehabilitation facilities, hospitals, and payors.
• Customer Concentration: No single payor accounts for more than 35% of total revenue. The top 10 Medicaid states represent 6% of total Company revenue for 2025.

Geographic Revenue Distribution:

• Top 10 States: Accounted for 53% of total revenue in 2025.
• Growth Markets: Actively expands its footprint through de novo locations and acquisitions in targeted key markets to maximize pharmacy and provider services overlap.

Competitive Intelligence

Market Structure & Dynamics

Industry Characteristics: The U.S. healthcare industry is highly competitive, with a trend towards value-based purchasing and increasing consolidation among payors and suppliers. The home infusion and specialty pharmacy markets are large and fragmented. Barriers to entry vary by state, with some states having Certificate of Need (CON) laws.

Competitive Positioning Matrix:

Direct Competitors

Primary Competitors:

• Pharmacy Solutions: Local, regional, and national pharmacies, including Option Care Health, Inc., Coram CVS/specialty infusion services (a division of CVS Health), Accredo Health Group, Inc. (a unit of Cigna), Optum Specialty Pharmacy (a subsidiary of OptumRx, which is a unit of the UnitedHealth Group), and Omnicare, Inc. (a division of CVS Health).
• Provider Services: Local, regional, and national providers of home health, hospice, rehab therapy, personal, primary care, and behavioral health services.

Competitive Response Strategy: BrightSpring Health Services, Inc. focuses on its integrated care model, high-quality service delivery, operational excellence, and strategic acquisitions to maintain its competitive advantage against vertically integrated competitors and those with greater financial resources. The Company also emphasizes its ability to attract and retain skilled personnel and adapt to evolving market demands.

Risk Assessment Framework

Strategic & Market Risks

• Market Dynamics: Highly competitive industry; changes to Medicare and Medicaid rates and payment methodologies; cost containment initiatives and post-payment audits by third-party payors; implementation of alternative payment models and managed care transitions; fluctuations in federal and state spending; changes in drug utilization, pricing, PBM contracts, and Medicare Part D/Medicaid reimbursement; changes in relationships with pharmaceutical suppliers.
• Technology Disruption: Risks associated with emerging AI technologies, including potential biases, data privacy concerns, and reliance on complex algorithms and third-party AI models.

Operational & Execution Risks

• Supply Chain Vulnerabilities: Dependency on pharmaceutical manufacturers, wholesalers, and distributors; risk of supply shortages, production disruptions, and quality issues; potential for suppliers to cancel contracts or change pricing.
• Geographic Concentration: Approximately 53% of revenue derived from 10 states, posing regional risk exposure.
• Capacity Constraints: Reliance on continual recruitment and retention of qualified personnel (nurses, pharmacists, therapists, caregivers); intense competition for skilled labor; potential for staff shortages to impact service quality and delivery.

Financial & Regulatory Risks

• Market & Financial Risks: Delays or non-collection of accounts receivable; quarterly fluctuations in operating results; substantial indebtedness of approximately $2.6 billion as of December 31, 2025; exposure to interest rate risk on variable-rate debt; potential for asset impairment of goodwill.
• Regulatory & Compliance Risks: Extensive federal, state, and local healthcare regulations (licensure, billing, fraud and abuse laws like Anti-Kickback Statute, Stark Law, False Claims Act); state corporate practice of medicine and fee-splitting laws; HIPAA and other data privacy and security laws (e.g., CCPA, CPRA, My Health My Data Act); ongoing governmental reviews, audits, and investigations (e.g., RAC, TPE, UPIC programs, DOJ, DEA investigations, including the Silver matter settlement and Embrace Hospice investigation); quality reporting requirements impacting Medicare reimbursement; Certificate of Need (CON) laws affecting market expansion.

Geopolitical & External Risks

• Geographic Dependencies: Significant portion of branded and generic drugs manufactured outside the United States.
• Trade Relations: Changes in tax or trade policies, tariffs, or trade relations between the U.S. and other countries could increase costs or disrupt supply chains.
• External Events: Impact of inclement weather, natural disasters, acts of terrorism, civil unrest, or pandemics on ability to provide services.

Innovation & Technology Leadership

Research & Development Focus: Core Technology Areas: BrightSpring Health Services, Inc. invests in new and improved Electronic Medical Records (EMR) and Enterprise Resource Planning (ERP) systems, cloud-based data lake and business intelligence capabilities, and automated technologies, including robotic process automation. Innovation Pipeline: Focuses on developing Home-Based Primary Care, transitional care management programs (like CCRx), and the Clinical (Nursing) Hub to optimize patient management, outcomes, and cost.

Intellectual Property Portfolio:

• Patent Strategy: Not explicitly detailed.
• Licensing Programs: Not explicitly detailed.
• IP Litigation: Currently a defendant in litigation regarding the use of its BrightSpring mark.

Technology Partnerships: BrightSpring Health Services, Inc. relies on third-party hardware, telecommunications, and software vendors for system maintenance and upgrades. It also engages cybersecurity consultants and software support vendors for risk management, monitoring, and testing of IT systems.

Leadership & Governance

Executive Leadership Team

Leadership Continuity: The Company prioritizes attracting and retaining compassionate and skilled caregivers, pharmacy professionals, and managerial staff through investments in compensation, benefits, and internal career pathways.

Board Composition: The Board of Directors oversees risk management, with the Audit Committee specifically responsible for information security and related risk management. Following secondary offerings in 2025, BrightSpring Health Services, Inc. is no longer a "controlled company" under Nasdaq rules. KKR Stockholder beneficially owns approximately 32.2% of the voting power of the common stock.

Human Capital Strategy

Workforce Composition:

• Total Employees: Over 23,500 full-time equivalent employees as of December 31, 2025.
• Skill Mix: Comprises dedicated clinicians, caregivers, field, corporate, and administrative support employees, managers, and leaders, supported by approximately 500 human resources professionals.

Talent Management: Acquisition & Retention: Employs a comprehensive strategy including traditional and digital recruiting, community events, and partnerships with educational institutions. Retention rates have improved year-over-year, with approximately 70% retention of clinical positions in home health care, hospice care, and rehab care from December 2024 to December 2025. Employee Value Proposition: Compensation has increased over 50% in the last four years, and employees have access to daily pay options. The Company is building internal career pathways and talent pipeline programs.

Diversity & Development:

• Development Programs: Offers new training curricula, leadership development, and enhanced tuition programs.
• Culture & Engagement: Guided by "LEGACY" core behaviors (Leadership, Environment, Get Going, Attitude, Communication, You) to foster a positive and inclusive work environment.

Environmental & Social Impact

Environmental Commitments:

• Climate Strategy: Not explicitly detailed in the provided filing.
• Carbon Neutrality: Not explicitly detailed in the provided filing.
• Renewable Energy: Not explicitly detailed in the provided filing.
• Supply Chain Sustainability: Not explicitly detailed in the provided filing.

Social Impact Initiatives: BrightSpring Health Services, Inc. is mission-driven, focusing on delivering high-quality care to complex patients to improve health outcomes and reduce costs. The Company advocates with policymakers for its clients/patients and employees and aims to provide accessible and beneficial services.

Business Cyclicality & Seasonality

Demand Patterns:

• Seasonal Trends: Results of operations fluctuate on a quarterly basis.
• Economic Sensitivity: The business is sensitive to federal and state budget decisions, and weak economic conditions could adversely affect government funding for programs. Demand for homecare services is expected to grow.
• Industry Cycles: The healthcare industry is labor-intensive. Pharmacy solutions tailored for the home environment are expected to grow faster than the overall pharmacy market, driven by the aging population.

Planning & Forecasting: The Company's planning and forecasting are based on management's industry knowledge and independent sources, consistent with its operating budget and strategic plan.

Regulatory Environment & Compliance

Regulatory Framework: Industry-Specific Regulations: BrightSpring Health Services, Inc. operates in a heavily regulated industry, subject to extensive federal, state, and local laws governing licensure, certification, billing, fraud and abuse (e.g., Anti-Kickback Statute, Stark Law, False Claims Act), corporate practice of medicine, fee-splitting, and controlled substances. The Company must comply with FDA and DEA regulations. International Compliance: Operations in Canada are subject to PIPEDA and similar provincial laws regarding personal information processing. Trade & Export Controls: Subject to the Prescription Drug Marketing Act and potential impacts from changes in U.S. trade policies, tariffs, or trade relations.

Legal Proceedings:

• Silver Matter: PharMerica settled a False Claims Act and state false claims acts complaint in May 2024 for $120.0 million, with $110.0 million paid in 2024 and $10.0 million in 2025.
• Ongoing Investigations: Embrace Hospice is subject to an ongoing investigation by the DOJ and DEA regarding potential violations of the False Claims Act and Controlled Substances Act related to hospice services.
• General Litigation: The Company is party to various other legal and administrative proceedings in the ordinary course of business, with accruals recorded for probable and estimable liabilities.

Tax Strategy & Considerations

Tax Profile:

• Effective Tax Rate: 24.0% for 2025, 27.7% for 2024.
• Geographic Tax Planning: Files numerous consolidated and separate income tax returns in U.S. federal and various state and foreign jurisdictions.
• Tax Reform Impact: The One Big Beautiful Bill Act (enacted July 4, 2025) and the Inflation Reduction Act of 2022 include provisions that may affect future tax obligations and utilization of interest expense carryforwards.

Insurance & Risk Transfer

Risk Management Framework:

• Insurance Coverage: BrightSpring Health Services, Inc. is self-insured for a substantial portion of its general and professional liability, automobile liability, workers’ compensation risks, and health benefits, subject to certain stop-loss coverage. The Company also maintains cyber errors and omissions insurance.
• Risk Transfer Mechanisms: Utilizes interest rate swap agreements to hedge a portion of its variable interest rate exposure, with $1.5 billion notional amount of outstanding debt fixed through these agreements as of December 31, 2025.